WASHINGTON, D.C., and TORONTO, CANADA, November 7, 2023—Everest Clinical Research (“Everest”), a leading full-service contract research organization (“CRO”) with deep expertise in biostatistics and statistical programming, today announced it has acquired August Research (“August”). Everest is a portfolio company of Arlington Capital Partners (“Arlington”), a Washington, D.C. based private equity firm with extensive experience investing in regulated industries. Financial terms were not disclosed.
August is a European CRO that provides Clinical Trial Services (“CTS”) and Pharmacovigilance (“PV”) services to a wide variety of pharmaceutical and biotechnology clients. The Company has worked on over 120 projects for Phase I-IV clinical trials across multiple therapeutic areas including cardiovascular, infectious disease, oncology and rare disease. The acquisition of August establishes a European location for Everest to scale operational and business development opportunities through the Company’s operations across 14 countries in Western and Eastern Europe. August founders Dana Leff Niedzielska and Lukasz Niedzielski will continue with the business post-transaction.
Malcolm Little, a Partner at Arlington Capital Partners, said, “The acquisition of August is highly strategic for Everest as it further expands our global service offering and establishes a beachhead in one of the largest clinical trial markets in the world. With the addition of several European offices to complement Everest’s existing presence in North America and Asia, Everest further engrains itself as a truly global CRO.”
Jin Dai, COO of Everest, added, “Dana and Lukasz have built a strong culture at August that aligns extremely well with the broader Everest organization. Their expertise in and dedication to the field of clinical research are truly impressive. We look forward to working together to build out our sophisticated biometrics and data management practice in Europe and introduce August’s clinical operations to our U.S. customer base.”
“As we were approaching the next chapter for August, we wanted a true partnership where we could achieve our visions for growth together” said Dana Niedzielska, CEO of August. “Jin, Irene and the entire Everest team, along with Arlington Capital, present the right opportunity for us to realize those objectives and be part of an organization providing exceptional quality, service and on-time delivery to help advance life-changing research.”
Bilal Noor, a Principal at Arlington Capital Partners, added, “Entering the European market and expanding CTS and PV service offerings further enhances Everest’s already broad capability set, allowing the combined business to better serve its diverse customer base. We are excited to work with Dana, Lukasz, Gergana, Maria and the rest of the August team and build on their successful track record, uniting our strengths to propel the business forward as a cohesive entity.”
DLA Piper served as legal advisor to Arlington Capital Partners. Fairmount Partners served as financial advisor and Miles & Stockbridge served as legal counsel to August Research.
About Everest Clinical Research Corporation
Everest is a full-service contract research organization (“CRO”) providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device industries. Everest serves some of the best-known companies and works with many of the most advanced drugs, biologics, and medical devices in development today. Founded in 2004, Everest has a strong foundation as a statistical and data management center of excellence. Building on this foundation, Everest has successfully developed and established itself as a full-service CRO. Operating primarily in North America, with headquarters located in Toronto, Canada, and additional offices in the United States, China and Taiwan, Everest is known in the industry for its high quality deliverables, superior customer service, and flexibility in meeting clients’ needs.
About Arlington Capital Partners
Arlington Capital Partners is a Washington, DC-based private equity firm that has managed approximately $7 billion in capital commitments. Arlington is focused on middle market investment opportunities in growth industries including healthcare, government services and technology, aerospace & defense, and business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enable Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their Company’s position as leading competitors in their field. For more information, visit Arlington Capital’s website at arlingtoncap.com and follow Arlington on Linkedin.
About Fairmount Partners
Fairmount Partners (www.fairmountpartners.com) is an independent merger and acquisition advisory firm focused on emerging growth and middle-market companies. Fairmount helps its clients complete mergers and acquisitions, raise funds for growth, acquisitions and liquidity, and design and improve their corporate development strategies. Fairmount’s clients include successful entrepreneurs, private equity-sponsored enterprises and global public companies. Fairmount’s Healthcare group has completed 179 transactions for clients in 23 countries throughout North and South America, Europe, Asia and Australia.
Contacts:
Neal McCarthy
Managing Director
neal.mccarthy@fairmountpartners.com
Cecilia Gleason
Director
Fairmount Partners 